Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
Therapeutic cancer vaccines represent a new class of agents in the treatment of cancer. Sipuleucel-T is an antigen-presenting cell-based vaccine that recently demonstrated a significant 4.8-month improvement in overall survival in advanced prostate cancer patients and was well tolerated. The findings of that study have been met with skepticism, primarily because the agent did not change initial disease progression and yet led to longer survival. Although the commonly accepted treatment paradigm suggests that treatments should initially decrease tumor volume, perhaps vaccines work differently. Vaccines may induce delayed responses not seen in the first few months of therapy or they may initiate a dynamic immune response that ultimately slows the tumor growth rate, resulting in longer survival. Subsequent therapies may also combine with the induced immune response, resulting in a combination that is more effective than conventional treatments alone. Also, other treatments may alter tumor-associated antigen expression, enhancing the immune response. Future trials are currently planned to investigate these hypotheses; however, the results of the sipuleucel-T vaccine in prostate cancer should not be dismissed. Results with another vaccine in prostate cancer are similar, perhaps suggesting a class effect. In a broader context, clinicians may need to reconsider how they measure success. Several agents have been approved that produce superior disease progression results, but do not affect overall survival. Given the toxicity and costs of cancer therapies, perhaps studies should put more weight on long-term survival endpoints than on short-term endpoints that may be less consequential.
Madan
Ravi A
RA
Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Gulley
James L
JL
Fojo
Tito
T
Dahut
William L
WL
D019985:Benchmarking; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D013997:Time Factors
D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen
Eur J Cancer. 2009 Jan;45(2):228-47
19097774
Nat Clin Pract Oncol. 2007 Mar;4(3):136-7
17327854
Clin Cancer Res. 2000 Jun;6(6):2175-82
10873066
Clin Cancer Res. 2008 Jun 1;14(11):3536-44
18519787
Clin Cancer Res. 2007 Jul 1;13(13):3776-82
17606707
Semin Immunol. 2010 Jun;22(3):113-24
20403709
Ann Pharmacother. 2008 Jan;42(1):91-8
18094343
Eur Urol. 2009 May;55(5):1112-23
19042080
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
16344461
Br J Radiol. 2004 Jan;77(913):74-5
14988145
JAMA. 2005 Jul 13;294(2):238-44
16014598
Cancer. 2008 Nov 1;113(9):2478-87
18785254
J Clin Oncol. 2003 Aug 15;21(16):3127-32
12915604
Curr Opin Mol Ther. 2002 Feb;4(1):76-9
11883698
Eur J Cancer. 2006 May;42(8):1031-9
16616487
J Clin Oncol. 2011 Apr 1;29(10):1252-60
21383283
J Clin Invest. 2008 Jun;118(6):1991-2001
18523649
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8
19564563
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):878-87
16467102
J Clin Oncol. 2006 Jul 1;24(19):3089-94
16809734
Cancer. 1981 Jan 1;47(1):207-14
7459811
Clin Cancer Res. 2005 Mar 15;11(6):2416-26
15788693
J Clin Oncol. 2009 Jun 10;27(17):2766-71
19380448
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Clin Cancer Res. 2008 May 15;14(10):3060-9
18483372
Cancer Res. 2001 May 1;61(9):3689-97
11325840
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
Novartis Found Symp. 1998;215:92-8; discussion 98-102, 186-90
9760573
Clin Cancer Res. 2005 May 1;11(9):3353-62
15867235
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77
16467101
J Clin Oncol. 2000 Dec 1;18(23):3894-903
11099318
Prostate. 2004 Aug 1;60(3):197-204
15176049
Oncology (Williston Park). 2009 May;23(6):546-53
19544696
Cancer Immunol Immunother. 2010 May;59(5):663-74
19890632
N Engl J Med. 2004 Oct 7;351(15):1513-20
15470214
Nat Immunol. 2002 Jul;3(7):611-8
12087419
Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11
19548854
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
Vaccine. 2007 Sep 27;25 Suppl 2:B89-96
17573164
J Clin Oncol. 2008 Mar 1;26(7):1148-59
18309951
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Clin Cancer Res. 2005 Jun 15;11(12):4430-6
15958627
BJU Int. 2009 Jun;103(12):1636-40
19154507
Oncologist. 2008 Oct;13(10):1046-54
18838440